Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Theravance Biopharma stock

Own Theravance Biopharma stock in just a few minutes.

Theravance Biopharma, Inc is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 359 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Theravance Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TBPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Theravance Biopharma share price

Use our graph to track the performance of TBPH stocks over time.

Theravance Biopharma shares at a glance

Information last updated 2021-03-10.
52-week range$14.48 - $31.35
50-day moving average $18.79
200-day moving average $17.95
Wall St. target price$31.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.05

Buy Theravance Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Theravance Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theravance Biopharma financials

Revenue TTM $71.9 million
Gross profit TTM $-189,096,000
Return on assets TTM -42.4%
Return on equity TTM 0%
Profit margin 0%
Book value $-2.42
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Theravance Biopharma shares

There are currently 3.4 million Theravance Biopharma shares held short by investors – that's known as Theravance Biopharma's "short interest". This figure is 0.6% down from 3.4 million last month.

There are a few different ways that this level of interest in shorting Theravance Biopharma shares can be evaluated.

Theravance Biopharma's "short interest ratio" (SIR)

Theravance Biopharma's "short interest ratio" (SIR) is the quantity of Theravance Biopharma shares currently shorted divided by the average quantity of Theravance Biopharma shares traded daily (recently around 353476.02094241). Theravance Biopharma's SIR currently stands at 9.55. In other words for every 100,000 Theravance Biopharma shares traded daily on the market, roughly 9550 shares are currently held short.

However Theravance Biopharma's short interest can also be evaluated against the total number of Theravance Biopharma shares, or, against the total number of tradable Theravance Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theravance Biopharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Theravance Biopharma shares in existence, roughly 50 shares are currently held short) or 0.1376% of the tradable shares (for every 100,000 tradable Theravance Biopharma shares, roughly 138 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Theravance Biopharma.

Find out more about how you can short Theravance Biopharma stock.

Theravance Biopharma share dividends

We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.

Theravance Biopharma share price volatility

Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $14.48 up to $31.35. A popular way to gauge a stock's volatility is its "beta".

TBPH.US volatility(beta: 0.93)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.9285. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).

Theravance Biopharma overview

Theravance Biopharma, Inc. , a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site